 BOSTON--BUSINESS WIRE--Gamida Cell Ltd. Nasdaq: GMDA, an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced in an oral presentation the updated and expanded results from a Phase 1 clinical study of GDA-201, an investigational, natural killer NK cell-based cancer immunotherapy for the treatment of patients with non-Hodgkin lymphoma NHL and multiple myeloma MM, at the 62nd American Society of Hematology ASH Annual Meeti 